PRC
ENTA icon

Pearl River Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Pearl River Capital’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-280
Closed -$26K – 337
2019
Q1 		$26K Buy
280
+178
+175% +$16K 0.06% 278
2018
Q4 		$7K Buy
+102
New +$7.82K 0.03% 642

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pearl River Capital's ENTA Position: Q2 2019 in Review

Pearl River Capital sold out of Enanta Pharmaceuticals (ENTA) in Q2 2019, closing a stake of 280 shares — an estimated $26K sold.

Pearl River Capital first reported a position in ENTA in Q4 2018 and held it in 2 quarters. The position peaked at $26K in Q1 2019. 194 funds tracked by Wall St. Rank hold ENTA as of Q2 2019.

  • Pearl River Capital reported no remaining Enanta Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Pearl River Capital sold 280 Enanta Pharmaceuticals shares in Q2 2019, an estimated $26K.
  • Pearl River Capital first reported a position in Enanta Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Pearl River Capital's Enanta Pharmaceuticals position peaked at $26K in Q1 2019.
  • 194 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2019.

Based on Pearl River Capital's 13F filing for Q2 2019, filed 12 Aug 2019.